Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

Italy: A recent analysis of the FDA Adverse Event Reporting System (FAERS) database has provided new insights into the safety ...

Amsterdam, Netherlands) A pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in ...

GLP-1RA vs insulin use was associated with improved cardiovascular and kidney outcomes among patients with type 2 diabetes on dialysis.

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists (GLP-1RA) market for diabetes and obesity, Novo Nordisk is in innovator gear ...

Patients should consult with their doctor to see which option is best for them. semaglutide GLP-1RA diabetes, obesity Shown to have positive effects in patients with MASH, but does not reduce fibrosis ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo ...

Ozempic and Wegovy are branded versions of semaglutide made by pharmaceutical company Novo Nordisk. Ozempic has been ...

Roche's diversified portfolio and ongoing GLP-1 developments offer decent upside with limited downside. Read more about RHHBY ...

New research shows that metabolic bariatric surgery offers substantial protective benefits for patients with chronic kidney ...

Given Wegovy is a semaglutide, there is very strong evidence it can help people lose weight and maintain this weight loss. A ...